David P Schenkein - Net Worth and Insider Trading
David P Schenkein Net Worth
The estimated net worth of David P Schenkein is at least $12 Million dollars as of 2023-03-20. David P Schenkein is the Director of Agios Pharmaceuticals Inc and owns about 467,733 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $11 Million. David P Schenkein is the Director of Denali Therapeutics Inc and owns about 57,464 shares of Denali Therapeutics Inc (DNLI) stock worth over $1 Million. David P Schenkein is also the Director of bluebird bio Inc and owns about 3,176 shares of bluebird bio Inc (BLUE) stock worth over $14,419. Details can be seen in David P Schenkein's Latest Holdings Summary section.
Transaction Summary of David P Schenkein
David P Schenkein Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, David P Schenkein owns 5 companies in total, including bluebird bio Inc (BLUE) , Denali Therapeutics Inc (DNLI) , and Agios Pharmaceuticals Inc (AGIO) among others .
Click here to see the complete history of David P Schenkein’s form 4 insider trades.
Insider Ownership Summary of David P Schenkein
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BLUE | bluebird bio Inc | 2013-06-18 | director |
| DNLI | Denali Therapeutics Inc | 2017-12-07 | director |
| AGIO | Agios Pharmaceuticals Inc | 2013-07-23 | director & 10 percent owner & Chief Executive Officer |
| FMI | Foundation Medicine Inc | 2016-06-16 | director |
| PRME | Prime Medicine Inc | 2022-10-19 | director |
David P Schenkein Latest Holdings Summary
David P Schenkein currently owns a total of 3 stocks. Among these stocks, David P Schenkein owns 467,733 shares of Agios Pharmaceuticals Inc (AGIO) as of March 13, 2023, with a value of $11 Million and a weighting of 88.92%. David P Schenkein owns 57,464 shares of Denali Therapeutics Inc (DNLI) as of December 21, 2020, with a value of $1 Million and a weighting of 10.96%. David P Schenkein also owns 3,176 shares of bluebird bio Inc (BLUE) as of August 31, 2017, with a value of $14,419 and a weighting of 0.12%.
Latest Holdings of David P Schenkein
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals Inc | 2023-03-13 | 467,733 | 23.26 | 10,879,470 |
| DNLI | Denali Therapeutics Inc | 2020-12-21 | 57,464 | 23.33 | 1,340,635 |
| BLUE | bluebird bio Inc | 2017-08-31 | 3,176 | 4.54 | 14,419 |
Holding Weightings of David P Schenkein
David P Schenkein Form 4 Trading Tracker
According to the SEC Form 4 filings, David P Schenkein has made a total of 11 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years, including 1 buys and 10 sells. The most-recent trade in Agios Pharmaceuticals Inc is the sale of 20,000 shares on March 13, 2023, which brought David P Schenkein around $449,800.
According to the SEC Form 4 filings, David P Schenkein has made a total of 4 transactions in Denali Therapeutics Inc (DNLI) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Denali Therapeutics Inc is the sale of 30,000 shares on December 21, 2020, which brought David P Schenkein around $3 Million.
According to the SEC Form 4 filings, David P Schenkein has made a total of 0 transactions in bluebird bio Inc (BLUE) over the past 5 years. The most-recent trade in bluebird bio Inc is the sale of 2,000 shares on August 31, 2017, which brought David P Schenkein around $230,140.
Insider Trading History of David P Schenkein
- 1
- 2
- 3
David P Schenkein Trading Performance
GuruFocus tracks the stock performance after each of David P Schenkein's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David P Schenkein is 51.54%. GuruFocus also compares David P Schenkein's trading performance to market benchmark return within the same time period. The performance of stocks bought by David P Schenkein within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how David P Schenkein's insider trading performs compared to the benchmark.
Performance of David P Schenkein
Average Relative Return
20.95%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | 36.07 | 51.54 | 32.75 | 20.95 | 10.64 | -5.17 |
| Relative Return to S&P 500(%) | 33.65 | 42.49 | 41.61 | 5.12 | -12.38 | -14.05 |
David P Schenkein Ownership Network
Ownership Network List of David P Schenkein
Ownership Network Relation of David P Schenkein
David P Schenkein Owned Company Details
What does bluebird bio Inc do?
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
Who are the key executives at bluebird bio Inc?
David P Schenkein is the director of bluebird bio Inc. Other key executives at bluebird bio Inc include Chief Business & Legal Officer Joseph Vittiglio , Chief Financial Officer Christopher Krawtschuk , and Chief Medical Officer Richard A Colvin .
bluebird bio Inc (BLUE) Insider Trades Summary
Over the past 18 months, David P Schenkein made no insider transaction in bluebird bio Inc (BLUE). Other recent insider transactions involving bluebird bio Inc (BLUE) include a net sale of 34,803 shares made by Andrew Obenshain , a net sale of 26,613 shares made by Jason Cole , and a net sale of 11,727 shares made by Nick Leschly .
In summary, during the past 3 months, insiders sold 8,025 shares of bluebird bio Inc (BLUE) in total and bought 0 shares, with a net sale of 8,025 shares. During the past 18 months, 83,426 shares of bluebird bio Inc (BLUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 83,426 shares.
bluebird bio Inc (BLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.
NAS:BLUE Insider Transactions
David P Schenkein Mailing Address
Above is the net worth, insider trading, and ownership report for David P Schenkein. You might contact David P Schenkein via mailing address: C/o Bluebird Bio, Inc., 840 Memorial Drive, Cambridge Ma 02139.
